Tvardi Therapeutics
TVRD
67 hedge funds and large institutions have $12.1M invested in Tvardi Therapeutics in 2025 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 30 increasing their positions, 8 reducing their positions, and 17 closing their positions.
275% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 8
2.11% more ownership
Funds ownership: 28% → 30.11% (+2.1%)
8% less funds holding
Funds holding: 73 → 67 (-6)
35% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 17
88% less capital invested
Capital invested by funds: $102M → $12.1M (-$90.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFG
American Financial Group
Cincinnati,
Ohio
|
+$2M |
| 2 |
Morgan Stanley
New York
|
+$723K |
| 3 |
SAM
Silvercrest Asset Management
New York
|
+$705K |
| 4 |
Renaissance Technologies
New York
|
+$666K |
| 5 |
BlackRock
New York
|
+$547K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$6.77M |
| 2 |
VPC
Vestal Point Capital
New York
|
-$6.51M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$3.22M |
| 4 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$2.53M |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$787K |
TVRD Hedge Fund Activity: Q4 2025 in Review
67 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q4 2025, worth a combined $12.1M — down 88% from $102M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of TVRD and 11 opened new positions — a net loss of 6 holders — while 8 trimmed existing stakes and 30 added.
The largest buyer was American Financial Group, opening a new position worth an estimated $2M. The largest seller was 683 Capital Management, exiting entirely with an estimated $6.77M sold.
- 67 institutional investors held Tvardi Therapeutics (TVRD) as of Q4 2025, down from 73 in Q3 2025.
- Funds reported $12.1M of Tvardi Therapeutics stock for Q4 2025, down 88% quarter-over-quarter.
- 11 funds opened new Tvardi Therapeutics positions in Q4 2025 and 17 closed out, a net change of -6 holders.
- The largest Tvardi Therapeutics buyer in Q4 2025 was American Financial Group, an estimated $2M added.
- The largest Tvardi Therapeutics seller in Q4 2025 was 683 Capital Management, an estimated $6.77M sold.
Based on aggregated 13F filings for Q4 2025.